CRA is proud to be an exhibiting sponsor of this ISPOR Europe 2018.
Seven of our consultants had 7 posters accepted into the Congress which will all be displayed throughout the exhibit hall, including our senior consultants Walter Colasante, Steve Kelly, and Justus Dehnen.
For more information on this event, click here, and see below for the posters presented at the event:
Impact of outcome-based annuities on small biotech companies
G-BA conditional approvals in the AMNOG procedure: Impact on HTA outcomes and price
Impact of the clinical trial design strategy on product market uptake and overall commercial success
UK health technology assessment of orphan drugs for rare oncology versus rare disease: Does orphan designation make any difference in HTA process?
The quantity and quality of evidence supporting European marketing authorisation of orphan drugs: Comparison of rare oncology versus rare disease
Are tradtionally managed entry agreements suitable for potentially curative gene/cell therapies?
Is adopting a low price strategy to gain market access compatible with a viable gene/cell therapy business?
Rare Disease: A year in review
As more investments have been made in developing and commercializing treatments for rare diseases, the experience and expertise of our CRA teams have grown....